Nektar Therapeutics Stock Forecast, Price & News

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last twelve months. There are currently 2 sell ratings, 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Nektar Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NKTR, but not buy additional shares or sell existing shares.
View analyst ratings for Nektar Therapeutics or view top-rated stocks.

12 Wall Street research analysts have issued 12 month price objectives for Nektar Therapeutics' shares. Their NKTR stock forecasts range from $3.00 to $54.00. On average, they expect Nektar Therapeutics' share price to reach $13.17 in the next year. This suggests a possible upside of 230.8% from the stock's current price.
View analysts' price targets for Nektar Therapeutics or view top-rated stocks among Wall Street analysts.

Nektar Therapeutics' stock was trading at $13.51 at the start of the year. Since then, NKTR shares have decreased by 70.5% and is now trading at $3.98.
View the best growth stocks for 2022 here.

Nektar Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Nektar Therapeutics.

Nektar Therapeutics (NASDAQ:NKTR) announced its earnings results on Thursday, May, 5th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, beating analysts' consensus estimates of ($0.72) by $0.23. The biopharmaceutical company had revenue of $24.82 million for the quarter, compared to analysts' expectations of $24.89 million. Nektar Therapeutics had a negative net margin of 476.58% and a negative trailing twelve-month return on equity of 65.64%. Nektar Therapeutics's quarterly revenue was up 5.0% on a year-over-year basis. During the same period last year, the business posted ($0.68) EPS.
View Nektar Therapeutics' earnings history.

46 employees have rated Nektar Therapeutics CEO Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among Nektar Therapeutics' employees.

Some companies that are related to Nektar Therapeutics include Johnson & Johnson (JNJ), Eli Lilly and (LLY), Pfizer (PFE), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Corcept Therapeutics (CORT), Pacira BioSciences (PCRX), Supernus Pharmaceuticals (SUPN) and Omeros (OMER).
View all of NKTR's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY).

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

Nektar Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Invesco Ltd. (19.99%), BlackRock Inc. (14.02%), Vanguard Group Inc. (10.43%), Primecap Management Co. CA (9.16%), State Street Corp (3.11%) and Bellevue Group AG (2.58%). Company insiders that own Nektar Therapeutics stock include Curet Myriam, Gil M Labrucherie, Gil M Labrucherie, Howard W Robin, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, Jillian B Thomsen, John Nicholson, John Northcott, Jonathan Zalevsky, Katharina Otto-Bernstein, Lutz Lingnau, Mark Andrew Wilson, Myriam Curet, R Scott Greer, Robert Chess and Stephen K Doberstein.
View institutional ownership trends for Nektar Therapeutics.

NKTR stock was sold by a variety of institutional investors in the last quarter, including Maverick Capital Ltd., BlackRock Inc., Strong Tower Advisory Services, Primecap Management Co. CA, Rhenman & Partners Asset Management AB, Blair William & Co. IL, State of Tennessee Treasury Department, and Financial Advocates Investment Management. Company insiders that have sold Nektar Therapeutics company stock in the last two years include Curet Myriam, Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, John Northcott, Jonathan Zalevsky, Mark Andrew Wilson, Myriam Curet, R Scott Greer, and Robert Chess.
View insider buying and selling activity for Nektar Therapeutics or view top insider-selling stocks.

NKTR stock was bought by a variety of institutional investors in the last quarter, including Group One Trading L.P., First Trust Advisors LP, Vanguard Group Inc., Simplex Trading LLC, Candriam Luxembourg S.C.A., Jane Street Group LLC, Edgestream Partners L.P., and PDT Partners LLC.
View insider buying and selling activity for Nektar Therapeutics or or view top insider-buying stocks.

Shares of NKTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NKTR stock can currently be purchased for approximately $3.98.

Nektar Therapeutics (NASDAQ:NKTR) has a market capitalization of $741.35 million and generates $101.91 million in revenue each year. The biopharmaceutical company earns $-523.84 million in net income (profit) each year or ($2.670010) on an earnings per share basis.

Nektar Therapeutics employs 740 workers across the globe.

Nektar Therapeutics was founded in 1990.

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The official website for Nektar Therapeutics is www.nektar.com. The biopharmaceutical company can be reached via phone at (415) 482-5300, via email at [email protected], or via fax at 415-339-5300.